← All trials
NCT01124643
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2010
- Primary completion
- Jul 1, 2013
- Completion date
- Jul 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- ShireLead sponsor
- Melbourne HealthOverall official - principal investigator
- University of TurkuOverall official - principal investigator
- O & O Alpan LLCOverall official - principal investigator
- University of IowaOverall official - principal investigator
- Szpital Uniwersytecki w KrakowieOverall official - principal investigator
- General Hospital Slovenj GradecOverall official - principal investigator
- Charles UniversityOverall official - principal investigator
- Salford Royal Foundation NHS TrustOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.